Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review (Q36956380)

17 August 2017

1 reference

title

Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review (English)

1 reference

17 August 2017

1

Bien E

1 reference

17 August 2017

Balcerska A

2

1 reference

PubMed ID

17906988

17 August 2017

language of work or name

1 reference

1 February 2008

1 reference

17 August 2017

1 reference

17 August 2017

13

1 reference

17 August 2017

1

1 reference

17 August 2017

1-26

1 reference

The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells

17 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Therapeutic enhancement of IL-2 through molecular design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Clinical advances in therapies targeting the interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The innate immune response to tumors and its role in the induction of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The dichotomous role of IL-2: tolerance versus immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Interleukin-2 and interleukin-15: immunotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Interleukin-2 receptor-directed therapies for cutaneous lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum evaluation of the balance between soluble interleukin-2 and interleukin-4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

MHC class I antigens, immune surveillance, and tumor immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Profile of soluble cytokine receptors in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Diurnal and sleep-wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serological immunomarkers in cutaneous T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Immunity against cancer: lessons learned from melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The role of anti-IL-2 receptor in high-risk kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Circulating soluble interleukin-2 receptor level predicts remission in very early reactive arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The biological significance of soluble interleukin-2 receptors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Tolerance, not immunity, crucially depends on IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Elevated Concentrations of Soluble IL-2 Receptor in both Bronchoalveolar Lavage Fluid and Serum in a Patient with BOOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Advances in interleukin 2 receptor targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Soluble interleukin-2 receptor in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Development of humanized antibodies as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Strikingly higher interleukin (IL)-1alpha, IL-1beta and soluble interleukin-1 receptor antagonist (sIL-1RA) but similar IL-2, sIL-2R, IL-3, IL-4, IL-6, sIL-6R, IL-10, tumour necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta and inte

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

A fresh look at tumor immunosurveillance and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The IL-2/IL-2 receptor system: a current overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Design of humanized antibodies: from anti-Tac to Zenapax

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The IL-2/IL-15 receptor systems: targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

On the role of sIL-2R measurements in rheumatoid arthritis and cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

The significance of soluble interleukin-2 receptor in monitoring disease relapse in patients with nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum soluble interleukin-2 receptor levels in patients with chronic hepatitis B virus infection and its relation with anti-HBc

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Serum soluble interleukin–2 receptor concentrations as an independent prognostic marker in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

Global Role of the Immune System in Identifying Cancer Initiation and Limiting Disease Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13547500701674063

10.1080/13547500701674063

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17906988